tetano
Editor, Senior Moderator
Front Immunol
. 2022 Jun 16;13:909011.
doi: 10.3389/fimmu.2022.909011. eCollection 2022.
Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection
Taif Shah[SUP] 1 [/SUP], Zahir Shah[SUP] 2 [/SUP], Nafeesa Yasmeen[SUP] 3 [/SUP], Zulqarnain Baloch[SUP] 1 [/SUP], Xueshan Xia[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is an infectious disease that poses severe threats to global public health and significant economic losses. The COVID-19 global burden is rapidly increasing, with over 246.53 million COVID-19 cases and 49.97 million deaths reported in the WHO 2021 report. People with compromised immunity, such as tuberculosis (TB) patients, are highly exposed to severe COVID-19. Both COVID-19 and TB diseases spread primarily through respiratory droplets from an infected person to a healthy person, which may cause pneumonia and cytokine storms, leading to severe respiratory disorders. The COVID-19-TB coinfection could be fatal, exacerbating the current COVID-19 pandemic apart from cellular immune deficiency, coagulation activation, myocardial infarction, and other organ dysfunction. This study aimed to assess the pathogenesis of SARS-CoV-2-Mycobacterium tuberculosis coinfections. We provide a brief overview of COVID19-TB coinfection and discuss SARS-CoV-2 host cellular receptors and pathogenesis. In addition, we discuss M. tuberculosis host cellular receptors and pathogenesis. Moreover, we highlight the impact of SARS-CoV-2 on TB patients and the pathological pathways that connect SARS-CoV-2 and M. tuberculosis infection. Further, we discuss the impact of BCG vaccination on SARS-CoV-2 cases coinfected with M. tuberculosis, as well as the diagnostic challenges associated with the coinfection.
Keywords: BCG vaccination; COVID-19; SARS-CoV-2-M. tuberculosis pathogenesis; coinfection; tuberculosis.
. 2022 Jun 16;13:909011.
doi: 10.3389/fimmu.2022.909011. eCollection 2022.
Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection
Taif Shah[SUP] 1 [/SUP], Zahir Shah[SUP] 2 [/SUP], Nafeesa Yasmeen[SUP] 3 [/SUP], Zulqarnain Baloch[SUP] 1 [/SUP], Xueshan Xia[SUP] 1 [/SUP]
Affiliations
- PMID: 35784278
- PMCID: PMC9246416
- DOI: 10.3389/fimmu.2022.909011
Abstract
Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is an infectious disease that poses severe threats to global public health and significant economic losses. The COVID-19 global burden is rapidly increasing, with over 246.53 million COVID-19 cases and 49.97 million deaths reported in the WHO 2021 report. People with compromised immunity, such as tuberculosis (TB) patients, are highly exposed to severe COVID-19. Both COVID-19 and TB diseases spread primarily through respiratory droplets from an infected person to a healthy person, which may cause pneumonia and cytokine storms, leading to severe respiratory disorders. The COVID-19-TB coinfection could be fatal, exacerbating the current COVID-19 pandemic apart from cellular immune deficiency, coagulation activation, myocardial infarction, and other organ dysfunction. This study aimed to assess the pathogenesis of SARS-CoV-2-Mycobacterium tuberculosis coinfections. We provide a brief overview of COVID19-TB coinfection and discuss SARS-CoV-2 host cellular receptors and pathogenesis. In addition, we discuss M. tuberculosis host cellular receptors and pathogenesis. Moreover, we highlight the impact of SARS-CoV-2 on TB patients and the pathological pathways that connect SARS-CoV-2 and M. tuberculosis infection. Further, we discuss the impact of BCG vaccination on SARS-CoV-2 cases coinfected with M. tuberculosis, as well as the diagnostic challenges associated with the coinfection.
Keywords: BCG vaccination; COVID-19; SARS-CoV-2-M. tuberculosis pathogenesis; coinfection; tuberculosis.